Disclaimer

Certain views expressed here contain information derived from publicly available sources that have not been independently verified.

The presentation includes certain statements, estimates and projections with respect to the anticipated future financial performance of Cyclopharm Limited and as to the markets for the company's products. Such statements, estimates and projections reflect various assumptions made by the directors concerning anticipated results, which assumptions may or may not prove to be correct. Cyclopharm Limited has not sought independent verification of information in this presentation.

While the directors believe they have reasonable grounds for each of the statements, estimates and projections and all care has been taken in the preparation, no representation or warranty, express or implied, is given as to the accuracy, completeness or correctness, likelihood of achievement or reasonableness of statements, estimates and projections contained in this presentation. Such statements, estimates and projections are by their nature subject to significant uncertainties, contingencies and assumptions.

To the maximum extent permitted by law, none of the Cyclopharm Limited, its directors, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of information contained in this presentation.

All references to dollars unless otherwise specified are to Australian dollars.
Profitable & Growing MedTech
underlying business is cash positive and issuing dividends

First in class proprietary product available in 57 countries and named as the agent of choice in the EANM Guidelines

Recurring revenue from consumables similar to an annuity model

USAFDA approval set to quadruple the size of the existing business on existing PE market

Optionality expanding into indications beyond PE could dwarf even the USA opportunity
Cyclopharm – an established company

- 1986: Technegas launched in Australia
- 57 countries via 1,500 Technegas customers
- 4M Technegas patient scans
- 80% recurring revenue via consumable sales
~3 million cases of PE p.a. but could be much higher

30% of pulmonary embolisms are fatal if left untreated

Symptoms are varied with presence confirmed either through CTPA or a nuclear medicine ventilation-perfusion study

Nuclear Medicine provides functional imaging
Technegas
world’s best functional lung ventilation technology

**Patient** inhales radioactive gas-like substance

**Clinician** can visualize functional ventilation to the alveolus (the site of gas exchange)
Benefits of using Technegas

- Easy to administer & non-invasive
- Only need 3 to 4 breaths
- 3D images provide functional imaging through to the alveolus
- No contraindications
- Cost effective
Superior to competitive nuclear medicine products

**Technegas**
- Easy
- 3 to 4 breaths
- 3D images
- No contraindications
- Cost-effective

**Xenon**
- True radioactive gas inhaled with full face mask
- Constant inhale-exhale breathing for 15 mins
- No 3D images limits views and resulting in inferior clinical outcomes
- Requires special rooms to contain radioactive gas in the event of a release

**DTPA**
- Wet Aerosol impacts efficacy and clinician interpretations
- Creates hotspots in presence of lung diseases, which is a frequent comorbidity in PE
Diagnosing Pulmonary Embolism in the USA

High radiation burden
At least 27 times more radiation to the breast patient compared to V/Q SPECT

Contraindications
Pregnancy, renal impairment, contrast material allergy, diabetes

AKI
Acute Kidney Injury occurs in up to 13% of CTPA cases

Clinical Sensitivity
Planar = 67%
CTPA = 82%
SPECT = 93%

Nuclear Medicine
Predominantly Planar Imaging

$90m USD nuclear medicine ventilation imaging market (Planar)

15% CTPA radiology
85% Planar Studies p.a.

4 million Studies p.a.

Opportunity to displace CTPA
Special Protocol Assessment (SPA) – terms of protocol design developed in consultation and agreed with USFDA

Interim 40 patient read results submitted with face to face meeting for 10 October 2018 at USFDA Headquarters

240 patient “all-comer” – wide cross section of diseases
70 patients imaged as at 30/08/2018

USFDA approval targeting H2 2019

Technegas Phase 3 USFDA clinical trial underway
Expanding the use of Technegas
Optionality providing significant growth potential beyond PE into patient management

USA Market
nuclear medicine ventilation imaging market to diagnose PE equal to $90m USD with reimbursement already in place

Targeting USA CTPA PE market
opportunity to convert CTPA to nuclear medicine imaging by converting to SPECT imaging

Half billion combined sufferers of Asthma and Chronic Obstructive Pulmonary Disease globally.
Trials underway
Clinical Studies Beyond PE Underway

Hunter Medical Research Institute
100 patient trial targeting phenotyping and response to therapy in severe asthma. 56 patients enrolled as at 03/09/2018

Woolcock Institute
100 patient trial to commence Q4 2018 targeting the diagnosis of mild to moderate COPD and response to therapy

Protocol development underway
Clinical trial to determine the effectiveness of early detection of COPD in asymptomatic smokers

Other clinical trials initiated
Lung Volume Reduction, assessment of Lung Transplant patients and early detection of COPD and response to therapy
Profitable & Growing MedTech underlying business is cash positive and issuing dividends.

First in class proprietary product available in 57 countries with 4 million studies to date.

Recurring revenue from consumables similar to an annuity model.

USFDA approval set to quadruple the size of the existing PE business and further leverage penetration into the CTPA market.

Optionality into indications beyond PE into chronic respiratory disease management could deliver exponential growth.
CYCLOPHARM (CYC)
FNN Presentation

4th September 2018
James McBrayer